BIO 2026

HIPRA Biotech Services Strengthens Agile Biologics Manufacturing Strategy

Redesigns development and manufacturing approach to support increasingly complex and fast-moving market needs.

BIO 2026

Johnson & Johnson to Acquire Firefly Bio for $1B

Firefly brings Firelink degrader antibody conjugate platform approach designed to deliver a highly selective protein degrader to tumor cells, while avoiding healthy cells.

BIO 2026

Lonza, Antharis Therapeutics Partner to Develop Novel Dual-Payload ADCs

Antharis’ proprietary antibody engineering and target biology expertise will be integrated with Lonza’s clinically validated, site-specific ADC technologies.

BIO 2026

Lonza Advances Integrated DNA to IND Programs with New GS Ori‑Go Vector Technology

Streamlined DNA‑to‑IND development delivers tox material in approximately two months, and IND readiness in as little as six months.

BIO 2026

Fareva Pilots New GMP Unit at Pau Site

Opens a new GMP Pilot Unit to produce liquid and lyophilized injectable forms.